186 related articles for article (PubMed ID: 35072228)
21. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
22. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
[TBL] [Abstract][Full Text] [Related]
23. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of a droplet digital PCR assay for detecting
Kim G; Lee SK; Suh DH; Kim K; No JH; Kim YB; Kim H
J Gynecol Oncol; 2022 Mar; 33(2):e15. PubMed ID: 34910396
[TBL] [Abstract][Full Text] [Related]
25. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
26. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract][Full Text] [Related]
27. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
28. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
[TBL] [Abstract][Full Text] [Related]
29. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
Wang M; Hui P
Arch Pathol Lab Med; 2021 Nov; 145(11):1367-1378. PubMed ID: 34673912
[TBL] [Abstract][Full Text] [Related]
30. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
[TBL] [Abstract][Full Text] [Related]
32. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
33. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
35. High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.
Zhang C; Zheng W
Semin Diagn Pathol; 2022 May; 39(3):176-186. PubMed ID: 34852949
[TBL] [Abstract][Full Text] [Related]
36. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract][Full Text] [Related]
37. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
[TBL] [Abstract][Full Text] [Related]
38. Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.
Banas T; Pitynski K; Okon K; Winiarska A
BMC Cancer; 2018 Apr; 18(1):418. PubMed ID: 29653556
[TBL] [Abstract][Full Text] [Related]
39. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
